Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature

Page, 1951, Treatment of lupus erythematosus with mepacrine, Lancet, 2, 755, 10.1016/S0140-6736(51)91643-1

Morand, 1992, Continuation of long-term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis, Ann Rheum Dis, 51, 1318, 10.1136/ard.51.12.1318

Anderson, 1996, Hydroxychloroquine therapy in rheumatic diseases, Bull Rheum Dis, 44, 6

Mackenzie, 1980, Chloroquine and hydroxychloroquine in rheumatological therapy, Clin Rheum Dis, 6, 545, 10.1016/S0307-742X(21)00317-9

Tett, 1988, A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers, Br J Clin Pharmacol, 26, 303, 10.1111/j.1365-2125.1988.tb05281.x

McChesney, 1983, Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate, Am J Med, 75, 11, 10.1016/0002-9343(83)91265-2

1991, A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus, N Engl J Med, 324, 150, 10.1056/NEJM199101173240303

Rudnicki, 1975, The efficacy of antimalarials in systemic lupus erythematosus, J Rheumatol, 2, 323

Scherbel, 1958, Further observations on the use of 4-aminoquinolone compounds in patients with rheumatoid arthritis or related diseases, Cleveland Clin Q, 25, 95, 10.3949/ccjm.25.2.95

Felson, 1990, The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis, Arthritis Rheum, 33, 1449, 10.1002/art.1780331001

Miller, 1991, Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients, DICP, 25, 1302, 10.1177/106002809102501202

Tett, 1989, Bioavailability of hydroxychloroquine tablets in healthy volunteers, Br J Pharmacol, 27, 771, 10.1111/j.1365-2125.1989.tb03439.x

Munster, 2002, Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis, Arthritis Rheum, 46, 1460, 10.1002/art.10307

McLachlan, 1994, Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis, Br J Rheumatol, 33, 235, 10.1093/rheumatology/33.3.235

Tett, 1994, Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of recemate, Chirality, 6, 355, 10.1002/chir.530060420

Mackenzie, 1983, Pharmacologic actions of 4-aminoquinolone compounds, Am J Med, 75, 5, 10.1016/0002-9343(83)91264-0

Tett, 2000, Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis, J Rheumatol, 27, 1656

Furst, 1996, Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases, Lupus, 5, 11, 10.1177/096120339600500104

Berliner, 1948, Studies on the chemotherapy of the human malarias: VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinolone, J Clin Invest, 27, 98, 10.1172/JCI101980

Wallace, 1994, Antimalarial agents and lupus, Rheum Dis Clin North Am, 20, 243, 10.1016/S0889-857X(21)00233-7

2000, Canadian rheumatology association, J Rheumatol, 27, 2919

Prouty, 1958, Spectrophotometric determination and distribution of chloroquine in human tissues, J Lab Clin Med, 52, 477

Bernstein, 1983, Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy, Am J Med, 75, 25, 10.1016/0002-9343(83)91267-6

McLachlan, 1993, Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate, Br J Clin Pharmacol, 36, 78, 10.1111/j.1365-2125.1993.tb05897.x

Fox, 1993, Mechanism of action of hydroxychloroquine as an antirheumatic drug, Semin Arthritis Rheum, 23, 82, 10.1016/S0049-0172(10)80012-5

Stauber, 1981, Inhibition of lysosomal function in red and white skeletal muscles by chloroquine, Exp Neurol, 71, 295, 10.1016/0014-4886(81)90090-X

Picot, 1991, Quinacrine inhibits tumor necrosis factor production by human macrophages in vitro, J Infect Dis, 164, 830, 10.1093/infdis/164.4.830

Salmeron, 1983, Immunosuppressive potential of antimalarials, Am J Med, 75, 19, 10.1016/0002-9343(83)91266-4

Panayi, 1973, Action of chloroquine phosphate in rheumatoid arthritis. I. Immunosuppressive effect, Ann Rheum Dis, 32, 316, 10.1136/ard.32.4.316

Liu, 2001, Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus, Asian Pac J Allergy Immunol, 19, 29, 10.1067/mai.2001.116004

Meng, 1997, Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine, Arthritis Rheum, 40, 927, 10.1002/art.1780400522

Homewood, 1972, Lysosomes, pH, and the antimalarial action of chloroquine, Nature, 235, 50, 10.1038/235050a0

Veinot, 1998, Chloroquine related cardiac toxicity, J Rheumatol, 25, 1221

Weissman, 1966, Lysosomes and joint disease, Arthritis Rheum, 9, 834, 10.1002/art.1780090611

Maksymowych, 1987, Antimalarials in rheumatology, Semin Arthritis Rheum, 16, 206, 10.1016/0049-0172(87)90023-0

MacDonald, 1970, Experimental chloroquine myopathy, J Neuropathol Exp Neurol, 29, 479, 10.1097/00005072-197007000-00010

Neville, 1979, Chloroquine-induced cytosomes with curvilinear profiles in muscle, Muscle Nerve, 2, 376, 10.1002/mus.880020509

Smith, 1966, Experimental chloroquine myopathy, J Neurol Neurosurg Psychiatr, 29, 255, 10.1136/jnnp.29.3.255

Rynes, 1983, Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment, Am J Med, 75, 35, 10.1016/0002-9343(83)91268-8

Bienfang, 2000, Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation, J Rheumatol, 27, 2703

Easterbrook, 1987, Dose relationships in patients with early chloroquine retinopathy, J Rheumatol, 14, 472

Nylander, 1966, Ocular damage in chloroquine therapy, Acta Ophthalmol, 44, 335, 10.1111/j.1755-3768.1966.tb08039.x

Sammartino, 1985, Ocular toxicity of systemic drugs, Am Fam Physician, 31, 226

Mavrikakis, 1996, Retinal toxicity in long term hydroxychloroquine treatment, Ann Rheum Dis, 55, 187, 10.1136/ard.55.3.187

Weiner, 1991, Hydroxychloroquine retinopathy, Am J Ophthalmol, 112, 528, 10.1016/S0002-9394(14)76853-9

Bernstein, 1991, Ocular safety of hydroxychloroquine, Ann Ophthalmol, 23, 292

Johnson, 1987, Hydroxychloroquine therapy in massive total doses without retinal toxicity, Am J Ophthalmol, 104, 139, 10.1016/0002-9394(87)90005-5

Tobin, 1982, Hydroxychloroquine, Arch Ophthalmol, 100, 81, 10.1001/archopht.1982.01030030083006

Levy, 1997, Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice, Arthritis Rheum, 40, 1482, 10.1002/art.1780400817

Spalton, 1993, Hydroxychloroquine, dosage parameters and retinopathy, Lupus, 2, 355, 10.1177/096120339300200604

Warner, 2001, Early hydroxychloroquine macular toxicity, Arthritis Rheum, 44, 1959, 10.1002/1529-0131(200108)44:8<1959::AID-ART334>3.0.CO;2-A

Marmor, 2002, Recommendations on screening for chloroquine and hydroxychloroquine retinopathy, Am J Ophthalmol, 109, 1377

Falcone, 1993, Hydroxychloroquine toxicity despite normal dose therapy, Ann Ophthalmol, 25, 385

Pavelka, 1989, Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis, Ann Rheum Dis, 48, 542, 10.1136/ard.48.7.542

Marks, 1982, Chloroquine retinopathy, Ann Rheum Dis, 41, 52, 10.1136/ard.41.1.52

McChesney, 1961, Laboratory studies of the 4-aminoquinolone antimalarials: I. Some biochemical characteristics of chloroquine, hydroxychloroquine, and SN-7718, Antibiot Chemother, 2, 800

Finbloom, 1985, Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity, J Rheumatol, 12, 692

Scherbel, 1957, Comparison of the effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthritis, Cleveland Clin Q, 24, 98, 10.3949/ccjm.24.2.98

Rynes, 1997, Antimalarial drugs in the treatment of rheumatological diseases, Br J Rheumatol, 36, 799, 10.1093/rheumatology/36.7.799

August, 1995, Histological and ultrastructural findings in chloroquine-induced cardiomyopathy, J Mol Med, 73, 73, 10.1007/BF00270580

Rewcastle, 1965, Vacuolar myopathy, Arch Neurol, 12, 570, 10.1001/archneur.1965.00460300018003

Estes, 1987, Chloroquine neuromyotoxicity, Am J Med, 82, 447, 10.1016/0002-9343(87)90444-X

Magnussen, 1977, Cardiomyopathy after chloroquine treatment, Acta Med Scand, 202, 429, 10.1111/j.0954-6820.1977.tb16857.x

Pearson, 1958, Vacuolar myopathy in systemic lupus erythematosus, Am J Clin Pathol, 29, 455, 10.1093/ajcp/29.5.455

Avina-Zubieta, 1995, Incidence of myopathy in patients treated with antimalarials, Br J Rheumatol., 34, 166, 10.1093/rheumatology/34.2.166

Petri, 1999, Systemic lupus erythematosus and the cardiovascular system: The heart. Systemic Lupus Erythematosus, 687

Richards, 1998, Hydroxychloroquine myopathy, J Rheumatol, 25, 1642

Wang, 1999, Discontinuation of antimalarial drugs in systemic lupus erythematosus, J Rheumatol, 26, 808

Seguin, 1995, Respiratory failure associated with hydroxychloroquine neuromyopathy [letter], Eur Neurol, 35, 236, 10.1159/000117135

Stein, 2000, Hydroxychloroquine neuromyotoxicity, J Rheumatol, 27, 2927

Don Michael, 1970, The effects of acute chloroquine poisoning with special reference to the heart, Am Heart J, 79, 831, 10.1016/0002-8703(70)90371-6

Lansimies, 1971, Acute cardiotoxicity of chloroquine and hydroxychloroquine in dogs, Ann Med Exp Biol Fenn, 49, 45

Nelson, 1948, Chloroquine; pathologic changes observed in rats which for two years had been fed various proportions, Arch Pathol, 45, 454

Marquardt, 2001, Treatment of hydroxychloroquine overdose, Am J Emerg Med, 19, 420, 10.1053/ajem.2001.25774

Ladipo, 1983, Complete heart block in chronic chloroquine poisoning, Int J Cardiol, 4, 198, 10.1016/0167-5273(83)90136-5

Edwards, 1978, Complete heart block due to chronic chloroquine toxicity managed with permanent pacemaker, Br Med J, 1, 1109, 10.1136/bmj.1.6120.1109

Baguet, 1999, Chloroquine cardiomyopathy with conduction disorders, Heart, 81, 221, 10.1136/hrt.81.2.221

Wray, 1975, Complete heart block and systemic lupus erythematosus, Br Heart J, 37, 982, 10.1136/hrt.37.9.982

Ratliff, 1987, Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy, N Engl J Med, 316, 191, 10.1056/NEJM198701223160405

McAllister, 1987, Chloroquine-induced cardiomyopathy, Arch Pathol Lab Med, 111, 953

Cubero, 1993, Restrictive cardiomyopathy caused by chloroquine, Br Heart J, 69, 451, 10.1136/hrt.69.5.451

Hughes, 1971, Chloroquine myopathy, Q J Med, 40, 85

Reuss-Borst, 1999, Complete heart block as a rare complication of treatment with chloroquine, J Rheumatol, 26, 1394

Cervera, 2001, Cardiac toxicity secondary to long term treatment with chloroquine [letter], Ann Rheum Dis, 60, 301, 10.1136/ard.60.3.301

1988, Weekly clinicopathological exercises, N Engl J Med, 319, 768

Godeau, 1981, Les troubles de conduction au cours du lupus érythémateux, Ann Med Interne, 132, 234

Verny, 1992, Troubles de la conduction cardiaque au cours d’un traitement prolongé par chloroquine, Presse Med, 21, 800

Whisnant, 1963, Chloroquine neuromyopathy, Mayo Clin Proc, 38, 501

Biji, 2000, Cardiac abnormalities in SLE, Lupus, 9, 236

Karrar, 2001, Coronary artery disease in systemic lupus erythematosus, Semin Arthritis Rheum, 30, 436, 10.1053/sarh.2001.23498

Bruce, 2000, Premature atherosclerosis in systemic lupus erythematosus, Rheum Dis Clin North Am, 26, 257, 10.1016/S0889-857X(05)70138-1

Manzi, 1997, Age-specificincidence rates of myocardial infarction and angina in women with systemic lupus erythematosus, Am J Epidemiol, 145, 408, 10.1093/oxfordjournals.aje.a009122

Petri, 1994, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus, Am J Med, 96, 254, 10.1016/0002-9343(94)90151-1

Rahman, 2000, Premature coronary artery disease in systemic lupus erythematosus in the absence of corticosteroid use [letter], J Rheumatol, 27, 1323

Minick, 1966, Experimental induction of athero-arteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet: I. Effect of repeated injection of horse serum in rabbits fed a dietary cholesterol supplement, J Exp Med, 124, 635, 10.1084/jem.124.4.635

Salmon, 2001, Accelerated atherosclerosis in systemic lupus erythematosus, Curr Opin Rheumatol, 13, 341, 10.1097/00002281-200109000-00001

Wallace, 1994, Antimalarial agents and lupus, Rheum Dis Clin North Am, 20, 243, 10.1016/S0889-857X(21)00233-7

Tett, 1993, Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis, J Rheumatol, 20, 1874

Laaksonen, 1974, Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus, Scand J Rheumatol, 3, 103, 10.3109/03009747409115809

Terra, 2002, Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics, Am J Cardiovasc Drugs, 2, 287, 10.2165/00129784-200202050-00001

Chien, 2000, Myocyte survival pathways and cardiomyopathy, Semin Oncol, 27, 9